Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.
Department of Health Products Policy and Standards, World Health Organization, Geneva, Switzerland.
Bull World Health Organ. 2024 Oct 1;102(10):722-729. doi: 10.2471/BLT.24.292359. Epub 2024 Aug 29.
The first version of the contained 186 medicines in 1977 and has evolved to include 502 medicines in 2023. Over time, different articles criticized the methods and process for decisions; however, the list holds global relevance as a model list to over 150 national lists. Given the global use of the model list, reflecting on its future role is imperative to understand how the list should evolve and respond to the needs of Member States. In 2023, the model list Expert Committee recommended the World Health Organization (WHO) to initiate a process to revise the procedures for updating the model list and the criteria guiding decisions. Here, we offer an agenda outlining priority areas and a vision for an authoritative model list. The main areas include improving transparency and trustworthiness of the recommendations; strengthening connection to national lists; and continuing the debate on the principles that should guide the model list, in particular the role of cost and price of essential medicines. These reflections are intended to support efforts ensuring the continued impact of this policy tool.
该清单的第一个版本于 1977 年包含 186 种药物，现已发展到 2023 年包含 502 种药物。随着时间的推移，不同的文章批评了决策的方法和过程；然而，该清单作为一个模型清单，对 150 多个国家的清单具有全球相关性。鉴于该模型清单在全球范围内的使用，反思其未来作用对于了解该清单应如何发展以及如何应对会员国的需求至关重要。2023 年，该模型清单专家委员会建议世界卫生组织（世卫组织）启动一个程序，修订更新该模型清单和指导决策的标准的程序。在这里，我们提供了一个议程，概述了优先领域和一个权威模型清单的愿景。主要领域包括提高建议的透明度和可信度；加强与国家清单的联系；并继续就指导该模型清单的原则进行辩论，特别是基本药物的成本和价格的作用。这些思考旨在支持确保这一政策工具持续产生影响的努力。
